Press Releases
Calidi is at the forefront of the genetic medicine revolution in cancer and other indications
Read the Latest
Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option
Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters’…
Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering
Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering SAN DIEGO, CA., August 20,…
Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights
Presented preclinical data at the American Society of Clinical Oncology (ASCO) on CLD-401 demonstrating biological…
Calidi Biotherapeutics Receives FDA Fast Track Designation for CLD-201 (SuperNova), a First-In-Class Stem-Cell Loaded Viral Therapy for the Treatment of Patients with Soft Tissue Sarcoma
Calidi Biotherapeutics Receives FDA Fast Track Designation for CLD-201 (SuperNova), a First-In-Class Stem-Cell Loaded Viral…
Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025
Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis…
Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds
Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds SAN DIEGO,…